Amylin Pharmaceuticals, Inc. Announces BYETTA Revenue
SAN DIEGO, July 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that unaudited net product sales for BYETTA(R) (exenatide) injection for the quarter ended June 30, 2006 were $98.6 million. These net product sales are being released in conjunction with today's financial results announced by Eli Lilly and Company, Amylin's collaboration partner for BYETTA.
Conference Call
Amylin will webcast its Quarterly Update Conference Call on July 24, 2006 at 5:00 p.m. ET/2:00 p.m. PT. The call will be webcast live through Amylin's corporate website, and a recording will be made available following the close of the call.
Ginger L. Graham, Amylin's Chief Executive Officer will lead the call. During the call, the Company plans to provide supporting details underlying its second quarter financial results, and information regarding key trends and assumptions for the remainder of 2006 operations. For those without access to the Internet, the live call may be accessed by phone by calling (866) 543-6407 (domestic) or (617) 213-8898 (international), passcode 78484689. A replay of the call will also be available by phone for 24 hours beginning approximately one hour after the close of the call and can be accessed at (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 52039618.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop promising therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1200 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com.
This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that the Company's final results for the second quarter of 2006 could differ materially from those described above as a result of the Company's customary quarterly financial closing procedures. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its most recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.
Amylin Pharmaceuticals, Inc.CONTACT: Mark Foletta, Senior Vice President, Finance and Chief FinancialOfficer of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com//